Anteris Technologies Global Corp. (AVR), a global medical technology company dedicated to advancing cardiac care, is approaching a clinical milestone in the upcoming quarter that warrants attention.
The company's lead product is DurAVR Transcatheter Heart Valve, designed to treat aortic stenosis, a potentially life-threatening condition caused by the narrowing of the aortic valve. This narrowing restricts blood flow from the heart to the body's main artery, the aorta, and subsequently to the rest of the body. Patients with severe aortic stenosis have a 50% risk of dying within 2 years.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com